71 related articles for article (PubMed ID: 20941610)
1. Myeloid-derived suppressor cells: characterization and expansion in models of endotoxemia and transplantation.
Van Rompaey N; Le Moine A
Methods Mol Biol; 2011; 677():169-80. PubMed ID: 20941610
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.
Greifenberg V; Ribechini E; Rössner S; Lutz MB
Eur J Immunol; 2009 Oct; 39(10):2865-76. PubMed ID: 19637228
[TBL] [Abstract][Full Text] [Related]
3. Subset characterization of myeloid-derived suppressor cells arising during induction of BM chimerism in mice.
Luyckx A; Schouppe E; Rutgeerts O; Lenaerts C; Koks C; Fevery S; Devos T; Dierickx D; Waer M; Van Ginderachter JA; Billiau AD
Bone Marrow Transplant; 2012 Jul; 47(7):985-92. PubMed ID: 22041852
[TBL] [Abstract][Full Text] [Related]
4. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
[TBL] [Abstract][Full Text] [Related]
5. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2.
Zhang Y; Liu Q; Zhang M; Yu Y; Liu X; Cao X
J Immunol; 2009 Mar; 182(6):3801-8. PubMed ID: 19265159
[TBL] [Abstract][Full Text] [Related]
6. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy.
Talmadge JE
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5243-8. PubMed ID: 17875751
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
Sinha P; Clements VK; Fulton AM; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4507-13. PubMed ID: 17483367
[TBL] [Abstract][Full Text] [Related]
8. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.
Haile LA; Gamrekelashvili J; Manns MP; Korangy F; Greten TF
J Immunol; 2010 Jul; 185(1):203-10. PubMed ID: 20525890
[TBL] [Abstract][Full Text] [Related]
9. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.
Ochoa AC; Zea AH; Hernandez C; Rodriguez PC
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):721s-726s. PubMed ID: 17255300
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of myeloid-derived suppressor cells.
Ugel S; Delpozzo F; Desantis G; Papalini F; Simonato F; Sonda N; Zilio S; Bronte V
Curr Opin Pharmacol; 2009 Aug; 9(4):470-81. PubMed ID: 19616475
[TBL] [Abstract][Full Text] [Related]
11. Endogenous glucocorticoids promote the expansion of myeloid-derived suppressor cells in a murine model of trauma.
Zhang K; Bai X; Li R; Xiao Z; Chen J; Yang F; Li Z
Int J Mol Med; 2012 Aug; 30(2):277-82. PubMed ID: 22664747
[TBL] [Abstract][Full Text] [Related]
12. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis.
Takahashi K; Prinz M; Stagi M; Chechneva O; Neumann H
PLoS Med; 2007 Apr; 4(4):e124. PubMed ID: 17425404
[TBL] [Abstract][Full Text] [Related]
13. The growing diversity and spectrum of action of myeloid-derived suppressor cells.
Mantovani A
Eur J Immunol; 2010 Dec; 40(12):3317-20. PubMed ID: 21110315
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells.
Nefedova Y; Fishman M; Sherman S; Wang X; Beg AA; Gabrilovich DI
Cancer Res; 2007 Nov; 67(22):11021-8. PubMed ID: 18006848
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
Haile LA; von Wasielewski R; Gamrekelashvili J; Krüger C; Bachmann O; Westendorf AM; Buer J; Liblau R; Manns MP; Korangy F; Greten TF
Gastroenterology; 2008 Sep; 135(3):871-81, 881.e1-5. PubMed ID: 18674538
[TBL] [Abstract][Full Text] [Related]
16. The roles of myeloid-derived suppressor cells in transplantation.
Wu T; Zhao Y; Zhao Y
Expert Rev Clin Immunol; 2014 Oct; 10(10):1385-94. PubMed ID: 25119260
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
[TBL] [Abstract][Full Text] [Related]
18. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
[TBL] [Abstract][Full Text] [Related]
19. Single bolus injection of bilirubin improves the clinical outcome in a mouse model of endotoxemia.
Kadl A; Pontiller J; Exner M; Leitinger N
Shock; 2007 Nov; 28(5):582-8. PubMed ID: 17577133
[TBL] [Abstract][Full Text] [Related]
20. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
Donkor MK; Lahue E; Hoke TA; Shafer LR; Coskun U; Solheim JC; Gulen D; Bishay J; Talmadge JE
Int Immunopharmacol; 2009 Jul; 9(7-8):937-48. PubMed ID: 19362167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
